Breaking Down the Parallel Performance of GROMACS, a High-Performance Molecular Dynamics Software
Authors:
Måns I. Andersson,
N. Arul Murugan,
Artur Podobas,
Stefano Markidis
Abstract:
GROMACS is one of the most widely used HPC software packages using the Molecular Dynamics (MD) simulation technique. In this work, we quantify GROMACS parallel performance using different configurations, HPC systems, and FFT libraries (FFTW, Intel MKL FFT, and FFT PACK). We break down the cost of each GROMACS computational phase and identify non-scalable stages, such as MPI communication during th…
▽ More
GROMACS is one of the most widely used HPC software packages using the Molecular Dynamics (MD) simulation technique. In this work, we quantify GROMACS parallel performance using different configurations, HPC systems, and FFT libraries (FFTW, Intel MKL FFT, and FFT PACK). We break down the cost of each GROMACS computational phase and identify non-scalable stages, such as MPI communication during the 3D FFT computation when using a large number of processes. We show that the Particle-Mesh Ewald phase and the 3D FFT calculation significantly impact the GROMACS performance. Finally, we discuss performance opportunities with a particular interest in develo** GROMACS for the FFT calculations.
△ Less
Submitted 29 August, 2022;
originally announced August 2022.
A Review on Parallel Virtual Screening Softwares for High Performance Computers
Authors:
Natarajan Arul Murugan,
Artur Podobas,
Davide Gadioli,
Emanuele Vitali,
Gianluca Palermo,
Stefano Markidis
Abstract:
Drug discovery is the most expensive, time demanding and challenging project in biopharmaceutical companies which aims at the identification and optimization of lead compounds from large-sized chemical libraries. The lead compounds should have high affinity binding and specificity for a target associated with a disease and in addition they should have favorable pharmacodynamic and pharmacokinetic…
▽ More
Drug discovery is the most expensive, time demanding and challenging project in biopharmaceutical companies which aims at the identification and optimization of lead compounds from large-sized chemical libraries. The lead compounds should have high affinity binding and specificity for a target associated with a disease and in addition they should have favorable pharmacodynamic and pharmacokinetic properties (grouped as ADMET properties). Overall, drug discovery is a multivariable optimization and can be carried out in supercomputers using a reliable scoring function which is a measure of binding affinity or inhibition potential of the drug-like compound. The major problem is that the number of compounds in the chemical spaces is huge making the computational drug discovery very demanding. However, it is cheaper and less time consuming when compared to experimental high throughput screening. As the problem is to find the most stable (global) minima for numerous protein-ligand complexes (at the order of 10$^6$ to 10$^{12}$), the parallel implementation of in-silico virtual screening can be exploited to make the drug discovery in affordable time. In this review, we discuss such implementations of parallelization algorithms in virtual screening programs. The nature of different scoring functions and search algorithms are discussed, together with a performance analysis of several docking softwares ported on high-performance computing architectures.
△ Less
Submitted 30 November, 2021;
originally announced December 2021.
